trial

Neural Biomarkers of Electroconvulsive Therapy Response

NCTId NCT04763655
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 75 (estimated)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2024-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
75 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2020-04-01
Primary completion
2024-12-01
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
clinical and neuropsychological testing

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institutes of Health (NIH)Collaborator

Investigators

1
Miklos Argyelan, MDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
75
Phase
NA
Primary Completion Date
2024-12-01
Status
RECRUITING
relationships
The graph out of here
drug
clinical and neuropsychological testing
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institutes of Health (NIH)
company
indication
Electroconvulsive Therapy Treated Patients
indication
investigator
Miklos Argyelan, MD
person